NEPH stock sentiment todayNephros Inc
Sentiment verdict
Gossip first, financials second — NEUTRAL at 65% confidence.
Last updated · cached analysis, refreshes periodically
NEPH
Nephros IncNephros is transitioning toward consistent profitability through recurring revenue, but low liquidity and lack of near-term catalysts keep it in a holding pattern.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for NEPH. Not financial advice.
Price · last 12 months
Gossip
The stock suffers from 'micro-cap silence' with very low daily volume and no recent major headlines. Market chatter focuses on the company's success in the Legionella prevention space and whether they can successfully pivot from clinical trials to broad commercial water filtration dominance.
- ·Growth in hospital-acquired infection (HAI) prevention mandates
- ·Potential for acquisition by a larger medical water purification player
- ·Slow adoption of DSU (Dual Stage Ultrafilter) in non-medical industrial settings
Financial
Nephros has achieved pockets of positive adjusted EBITDA and shows a healthy gross margin (~50%). While the balance sheet is relatively clean of long-term debt, revenue growth has been lumpy and the path to sustained GAAP net income remains thin.
- ·Gross Margins consistently above 50%
- ·Recurring revenue (filters) represents >80% of total sales
- ·Cash runway is sufficient but lacks capital for aggressive M&A
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Hollow — insiders are stepping back and the register is short-horizon.
- ·No open-market insider trades in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Extreme low liquidity makes exiting large positions difficult without price slippage
- ·Dependency on hospital capital expenditure budgets which are currently strained
- ·Regulatory shifts in EPA or CDC guidelines regarding water safety
Peer temperature
How direct competitors stack up against NEPH right now.
- HOTTMOThermo Fisher Scientific
HOTTER — Offers a massive, diversified portfolio and superior institutional liquidity that NEPH lacks.
See full analysis → - HOTPHParker-Hannifin
HOTTER — Boasts significantly higher industrial scale and dividends, though with less specific focus on medical ultrafiltration.
See full analysis → - NEUTRALPENTPentair plc
COLDER — Trading at a richer valuation relative to its slower organic growth in the residential water segment compared to NEPH's medical niche.
See full analysis →
- NEPH+5.9%
- TMO-0.3%
- PH-12.0%
- PENT—
Analyst price target
Consensus average of 2 analysts · median 8.00
Source: StockAnalysis.com · updated 2026-08-13
AI-generated analysis for informational purposes only. Not financial advice.